Inhibition of Src reduces gemcitabine-induced cytotoxicity in human pancreatic cancer cell lines

Cancer Letters

Volumn 260, Issue 1-2, 2008, Pages 155-162

  Ichihara, Naoto ^a   Kubota, Yoshitsugu ^a   Kitanaka, Akira ^a   Tanaka, Terukazu ^a   Taminato, Tomohiko ^a  

^a KAGAWA UNIVERSITY   (Japan)

Author keywords

Gemcitabine; Pancreatic cancer; PP2; Src

Indexed keywords

COMPLEMENTARY DNA; DIMETHYL SULFOXIDE; GEMCITABINE; MONOCLONAL ANTIBODY; PHOSPHOTYROSINE; POLYCLONAL ANTIBODY; PROTEIN TYROSINE KINASE;

ARTICLE; CANCER CELL CULTURE; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DNA SEQUENCE; DOWN REGULATION; DRUG CYTOTOXICITY; GROWTH INHIBITION; HUMAN; HUMAN CELL; ONCOGENE SRC; PANCREAS CANCER; POLYACRYLAMIDE GEL ELECTROPHORESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; WESTERN BLOTTING;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CULTURE MEDIA; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MUTATION; PANCREATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; PYRIMIDINES; SERUM; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES; TRANSFECTION;

AGOUTI PACA;

EID: 38349050566     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2007.10.035     Document Type: Article

References (38)

1. Lockhart A.C., Rothenberg M.L., and Berlin J.D. Treatment for pancreatic cancer: current therapy and continued progress. Gastroenterology 128 (2005) 1642-1654
2. Mancuso A., Calabro F., and Sternberg C.N. Current therapies and advances in the treatment of pancreatic cancer. Crit. Rev. Oncol. Hematol. 58 (2006) 231-241
3. Eckel F., Schneider G., and Schmid R.M. Pancreatic cancer: a review of recent advances. Expert Opin. Investig. Drugs 15 (2006) 1395-1410
4. Abbruzzese J.L. New applications of gemcitabine and future directions in the management of pancreatic cancer. Cancer 95 (2002) 941-945
5. Cooper J.A., and Howell B. The when and how of Src regulation. Cell 73 (1993) 1051-1054
6. Thomas S.M., and Brugge J.S. Cellular functions regulated by SRC family kinases. Annu. Rev. Cell. Dev. Biol. 13 (1997) 513-609
7. Schlessinger J. New roles for Src kinases in control of cell survival and angiogenesis. Cell 100 (2000) 293-296
8. Blume-Jensen P., and Hunter T. Oncogenic kinase signalling. Nature 411 (2001) 355-365
9. Irby R.B., and Yeatman T.J. Role of Src expression and activation in human cancer. Oncogene 19 (2000) 5636-5642
10. Summy J.M., and Gallick G.E. Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev. 22 (2003) 337-358
11. Alvarez R.H., Kantarjian H.M., and Cortes J.E. The role of Src in solid and hematologic malignancies: Development of new-generation src inhibitors. Cancer 107 (2006) 1918-1929
12. Lutz M.P., Esser I.B., Flossmann-Kast B.B., Vogelmann R., Luhrs H., Friess H., Buchler M.W., and Adler G. Overexpression and activation of the tyrosine kinase Src in human pancreatic carcinoma. Biochem. Biophys. Res. Commun. 243 (1998) 503-508
13. Menke A., Philippi C., Vogelmann R., Seidel B., Lutz M.P., Adler G., and Wedlich D. Down-regulation of E-cadherin gene expression by collagen type I and type III in pancreatic cancer cell lines. Cancer Res. 61 (2001) 3508-3517
14. Noble M.E., Endicott J.A., and Johnson L.N. Protein kinase inhibitors: insights into drug design from structure. Science 303 (2004) 1800-1805
15. Chen J., Röcken C., Nitsche B., Hosius C., Gschaidmeier H., Kahl S., Malfertheiner P., and Ebert M.P. The tyrosine kinase inhibitor imatinib fails to inhibit pancreatic cancer progression. Cancer Lett. 233 (2006) 328-337
16. Duxbury M.S., Ito H., Zinner M.J., Ashley S.W., and Whang E.E. Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells. Clin. Cancer Res. 10 (2004) 2307-2318
17. Duxbury M.S., Ito H., Zinner M.J., Ashley S.W., and Whang E.E. siRNA directed against c-Src enhances pancreatic adenocarcinoma cell gemcitabine chemosensitivity. J. Am. Coll. Surg. 198 (2004) 953-959
18. Yezhelyev M.V., Koehl G., Guba M., Brabletz T., Jauch K.W., Ryan A., Barge A., Green T., Fennell M., and Bruns C.J. Inhibition of SRC tyrosine kinase as treatment for human pancreatic cancer growing orthotopically in nude mice. Clin. Cancer Res. 10 (2004) 8028-8036
19. Trevino J.G., Summy J.M., Lesslie D.P., Parikh N.U., Hong D.S., Lee F.Y., Donato N.J., Abbruzzese J.L., Baker C.H., and Gallick G.E. Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model. Am. J. Pathol. 168 (2006) 962-972
20. Kleespies A., Jauch K.W., and Bruns C.J. Tyrosine kinase inhibitors and gemcitabine: new treatment options in pancreatic cancer?. Drug Resist. Updat. 9 (2006) 1-18
21. Kitanaka A., Suzuki T., Ito C., Nishigaki H., Coustan-Smith E., Tanaka T., Kubota Y., and Campana D. CD38-mediated signaling events in murine pro-B cells expressing human CD38 with or without its cytoplasmic domain. J. Immunol. 162 (1999) 1952-1958
22. Mukhopadhyay D., Tsiokas L., Zhou X.M., Foster D., Brugge J.S., and Sukhatme V.P. Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation. Nature 375 (1995) 577-581
23. Okutani Y., Kitanaka A., Tanaka T., Kamano H., Ohnishi H., Kubota Y., Ishida T., and Takahara J. Src directly tyrosine-phosphorylates STAT5 on its activation site and is involved in erythropoietin-induced signaling pathway. Oncogene 20 (2001) 6643-6650
24. Kitanaka A., Mano H., Conley M.E., and Campana D. Expression and activation of the nonreceptor tyrosine kinase Tec in human B cells. Blood 91 (1998) 940-948
25. Kubota Y., Tanaka T., Kitanaka A., Ohnishi H., Okutani Y., Waki M., Ishida T., and Kamano H. Src transduces erythropoietin-induced differentiation signals through phosphatidylinositol 3-kinase. EMBO J. 20 (2001) 5666-5677
26. Frankfurt O.S., and Krishan A. Identification of apoptotic cells by formamide-induced DNA denaturation in condensed chromatin. J. Histochem. Cytochem. 49 (2001) 369-378
27. Morla A.O., and Wang J.Y. Protein tyrosine phosphorylation in the cell cycle of BALB/c 3T3 fibroblasts. Proc. Natl. Acad. Sci. USA 83 (1986) 8191-8195
28. Johnson L.N., Noble M.E., and Owen D.J. Active and inactive protein kinases: structural basis for regulation. Cell 85 (1996) 149-158
29. Hanke J.H., Gardner J.P., Dow R.L., Changelian P.S., Brissette W.H., Weringer E.J., Pollok B.A., and Connelly P.A. Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation. J. Biol. Chem. 271 (1996) 695-701
30. Grant S., and Dent P. Kinase inhibitors and cytotoxic drug resistance. Clin. Cancer Res. 10 (2004) 2205-2207
31. Kaufman R.J. Vectors used for expression in mammalian cells. Methods Enzymol. 185 (1990) 487-511
32. Boudny V., and Nakano S. Src tyrosine kinase augments taxotere-induced apoptosis through enhanced expression and phosphorylation of Bcl-2. Br. J. Cancer 86 (2002) 463-469
33. Boudny V., and Nakano S. Src tyrosine kinase but not activated Ras augments sensitivity to taxanes through apoptosis in human adenocarcinoma cells. Anticancer Res. 23 (2003) 7-12
34. Cuadrado A., Garcia-Fernandez L.F., Gonzalez L., Suarez Y., Losada A., Alcaide V., Martinez T., Fernandez-Sousa J.M., Sanchez-Puelles J.M., and Munoz A. Aplidin induces apoptosis in human cancer cells via glutathione depletion and sustained activation of the epidermal growth factor receptor, Src, JNK, and p38 MAPK. J. Biol. Chem. 278 (2003) 241-250
35. Kolb A., Kleeff J., Arnold N., Giese N.A., Giese T., Korc M., and Friess H. Expression and differential signaling of heregulins in pancreatic cancer cells. Int. J. Cancer 120 (2007) 514-523
36. Rocha Lima C.M., and Flores A.M. Gemcitabine doublets in advanced pancreatic cancer: should we move on?. J. Clin. Oncol. 24 (2006) 327-329
37. Parsons J.T., and Parsons S.J. Src family protein tyrosine kinases: cooperating with growth factor and adhesion signaling pathways. Curr. Opin. Cell Biol. 9 (1997) 187-192
38. Haskell M.D., Slack J.K., Parsons J.T., and Parsons S.J. c-Src tyrosine phosphorylation of epidermal growth factor receptor, P190 RhoGAP, and focal adhesion kinase regulates diverse cellular processes. Chem. Rev. 101 (2001) 2425-2440